RecruitingPhase 2NCT07161037
Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW)
Studying Autosomal dominant polycystic kidney disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Vertex Pharmaceuticals Incorporated
- Intervention
- VX-407(drug)
- Enrollment
- 24 enrolled
- Eligibility
- 18-65 years · All sexes
- Timeline
- 2025 – 2027
Study locations (30)
- Alabama Kidney Research, Alabaster, Alabama, United States
- University of Alabama at Birmingham- Nephrology Research Clinic, Birmingham, Alabama, United States
- Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States
- UCSF Clinical Research Center at Parnassus, San Francisco, California, United States
- Nephrology & Hypertension Associates, PC, Middlebury, Connecticut, United States
- Yale University - Yale Nephrology Clinical Research Clinic, New Haven, Connecticut, United States
- Mayo Clinic - Jacksonville, Jacksonville, Florida, United States
- Emory School of Medicine - Renal Division, Atlanta, Georgia, United States
- Renal Associates, Columbus, Georgia, United States
- UChicago Medicine - Duchossois Center for Advanced Medicine - Nephrology, Chicago, Illinois, United States
- University of Iowa Health Care Medical Center- Nephrology, Iowa City, Iowa, United States
- The University of Kansas Medical Center Division of Nephrology, Kansas City, Kansas, United States
- University of Maryland Medical Center - General Clinical Research Center, Baltimore, Maryland, United States
- Tufts Medical Center, Boston, Massachusetts, United States
- Beth Israel Deaconess Medical Center - Nephrology, Boston, Massachusetts, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07161037 on ClinicalTrials.govOther trials for Autosomal dominant polycystic kidney disease
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07454174Metabolic Impacts of Ren-Nu: A Dietary Program for Polycystic Kidney DiseaseRichard Fatica
- RECRUITINGPHASE1NCT07228364Safety, Tolerability and Pharmacokinetics of AZD1613 in Adults With Autosomal Dominant Polycystic Kidney DiseaseAstraZeneca
- RECRUITINGNCT06970028Somatosensory Phenotyping of ADPKDUniversitaire Ziekenhuizen KU Leuven
- RECRUITINGNCT07260071Hypertension in Children and Young People at Risk of Autosomal Dominant Polycystic Kidney DiseaseKing's College London
- ACTIVE NOT RECRUITINGNCT07016282Simulated and Synthetic Health Data: Improving Clinical Research on Rare Diseases. A Real-World Data Simulation of Autosomal Dominant Polycystic Kidney Disease (ADPKD) Trials. A Retrospective, Observational StudyMario Negri Institute for Pharmacological Research
- RECRUITINGPHASE2NCT06902558A Study to Assess Adverse Events and Effectiveness of IntraVenous Infusions of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)AbbVie
- RECRUITINGPHASE1NCT06714006Phase 1 Study to Evaluate the Safety and Tolerability of Intravenously Administered PYC-003PYC Therapeutics
- RECRUITINGPHASE2NCT06800651Trial of JMKX003142 in Participants With Rapidly Progressive Autosomal Dominant Polycystic Kidney Disease (ADPKD)Jemincare
See all trials for Autosomal dominant polycystic kidney disease →